128 related articles for article (PubMed ID: 6619294)
1. Proposed zone standards for interpretation of fortimicin A disk diffusion tests.
Barry AL; Thornsberry C; Jones RN
J Clin Microbiol; 1983 Aug; 18(2):440-2. PubMed ID: 6619294
[TBL] [Abstract][Full Text] [Related]
2. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Gavan TL; Gerlach EH; Sommer HM
Eur J Clin Microbiol; 1984 Dec; 3(6):531-7. PubMed ID: 6441709
[TBL] [Abstract][Full Text] [Related]
3. Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.
Barry AL; Thornsberry C; Jones RN; Gerlach EH
Antimicrob Agents Chemother; 1980 Oct; 18(4):616-21. PubMed ID: 7447420
[TBL] [Abstract][Full Text] [Related]
4. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
[TBL] [Abstract][Full Text] [Related]
5. Cefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.
Wright DN; Welch DF; Saxon BA; Clark SJ; Matsen JM
Antimicrob Agents Chemother; 1982 Sep; 22(3):493-8. PubMed ID: 6215895
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin susceptibility tests by the single-disk agar diffusion technique.
Barry AL; Thornsberry C; Badal RE; Baker CN; Jones RN; Gerlach EH
Antimicrob Agents Chemother; 1979 Sep; 16(3):378-85. PubMed ID: 507794
[TBL] [Abstract][Full Text] [Related]
7. Proposed disk diffusion susceptibility criteria for ofloxacin.
Fuchs PC; Barry AL; Jones RN; Thornsberry C
J Clin Microbiol; 1985 Aug; 22(2):310-1. PubMed ID: 3861612
[TBL] [Abstract][Full Text] [Related]
8. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.
Fuchs PC; Jones RN; Barry AL
J Clin Microbiol; 1990 Mar; 28(3):608-9. PubMed ID: 2108997
[TBL] [Abstract][Full Text] [Related]
9. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).
Shungu DL; Weinberg E; Gadebusch HH
Antimicrob Agents Chemother; 1983 Feb; 23(2):256-60. PubMed ID: 6220671
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of teicoplanin and vancomycin disk susceptibility tests.
Barry AL; Thornsberry C; Jones RN
J Clin Microbiol; 1986 Jan; 23(1):100-3. PubMed ID: 2939101
[TBL] [Abstract][Full Text] [Related]
11. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Zerva L; Biedenbach DJ; Jones RN
J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1987 May; 7(1):77-82. PubMed ID: 3691036
[TBL] [Abstract][Full Text] [Related]
13. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
Jones RN; Erwin ME; Barrett MS
Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
[TBL] [Abstract][Full Text] [Related]
14. Fortimicins A and B, new aminoglycoside antibiotics. IV. In vitro study of fortimicin A compared with other aminoglycosides.
Girolami RL; Stamm JM
J Antibiot (Tokyo); 1977 Jul; 30(7):564-70. PubMed ID: 19409
[TBL] [Abstract][Full Text] [Related]
15. Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines.
Jones RN; Barry AL; Thornsberry C
J Clin Microbiol; 1983 Jul; 18(1):211-4. PubMed ID: 6350348
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
[TBL] [Abstract][Full Text] [Related]
18. Cefixime disk susceptibility test criteria.
Fuchs PC; Barry AL; Jones RN
J Clin Microbiol; 1986 Oct; 24(4):647-9. PubMed ID: 3771755
[TBL] [Abstract][Full Text] [Related]
19. Interpretive criteria for temocillin disk diffusion susceptibility testing.
Fuchs PC; Barry AL; Thornsberry C; Jones RN
Eur J Clin Microbiol; 1985 Feb; 4(1):30-3. PubMed ID: 3872793
[TBL] [Abstract][Full Text] [Related]
20. Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics.
Jones RN; Thornsberry C; Barry AL; Packer RR; Baker CN; Badal RE
Antimicrob Agents Chemother; 1980 Nov; 18(5):773-9. PubMed ID: 7447431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
